This GLK+ Th17 population will help in the selection of SLE patients that are responsive to GLK inhibitors (e.g., verteporfin), which block RORγt–AhR-complex-induced IL-17A production. This evidence concerns the gene MAP4K3 and systemic lupus erythematosus.